Cellular and humoral mechanisms of specific immunotherapy (SIT) in respiratory type-I-allergies.
Recruiting
- Conditions
- Allergic rhinoconjunctivitis and/or allergic asthma against birch pollenJ30.1J45.0H10.1Allergic rhinitis due to pollenPredominantly allergic asthmaAcute atopic conjunctivitis
- Registration Number
- DRKS00000116
- Lead Sponsor
- Klinik für Dermatologie und AllergologiePhilipps-Universität Marburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Rhinoconjunctivitis allergica or allergic asthma with maximal symptoms in the springtime.
Immediate-type sensitisation against birch pollen in clincial tests: positive skin prick test or intracutaneous test against birch pollen.
Positive nasal provocation against birch pollen.
Sensitisation against birch pollen (and the major allergen Bet v 1) detectable in vitro.
Specific IgE at least of CAP-class 2 (against the classical birch pollen allergen) and at least of CAP-class 1 against recombinant Bet v 1.
Signed declaration of consent.
Exclusion Criteria
Contraindication against specific immunotherapy.
Patients unable to give informed consent.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Induction of regulatory T cells;<br>Taking of blood samples before and 1, 3, 6, 12, 18, 24, 30, 36, 42, 48 months after initiation of SIT;<br>Determination of allergen-specific Treg and Teff frequencies as well as quantification of cytokines and specific antibodies
- Secondary Outcome Measures
Name Time Method